Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Histopathologic variables predict Oncotype DX recurrence score.

Melina B Flanagan1, David J Dabbs, Adam M Brufsky

  • 1Department of Pathology, Magee-Women's Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA.

Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|March 25, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lumpectomy Margins and Local Recurrence in DCIS: Results From the NRG Oncology/NSABP B-35 Randomized Clinical Trial.

JAMA surgery·2026
Same author

Prediction of Anthracycline Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer by the MammaPrint 70-Gene Signature for Patients Enrolled in the FLEX Study.

JCO precision oncology·2026
Same author

SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer.

NPJ breast cancer·2026
Same author

Comparative effectiveness of CDK4/6 inhibitors in metastatic breast cancer: using the target trial emulation framework to investigate overall survival in routine care.

Breast cancer research and treatment·2026
Same author

Magee Equation 3 demonstrates predictive and prognostic value for neoadjuvant chemotherapy outcomes in estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.

American journal of clinical pathology·2026
Same author

Enhancing therapeutic outcomes with artificial intelligence for HR-positive, HER2-negative metastatic breast cancer.

Cancer cell·2026
Same journal

Expanding the Spectrum of High-Risk Human Papilloma Virus (HPV)-Associated Glandular Neoplasms of the Anorectum.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026
Same journal

Deep Learning for Differentiating Pulmonary Metastasis from Primary Lung Cancer Constructed on Frozen Sections for Intraoperative Diagnosis.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026
Same journal

Margin Adequacy in Phyllodes Tumours Revisited: Reappraisal of the Evidence Base and Knowledge Gaps.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026
Same journal

Genomic Characterization of Classic Adamantinoma, Osteofibrous Dysplasia, and Osteofibrous Dysplasia-like Adamantinoma.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026
Same journal

Immunophenotypic, Cytogenetic, and Molecular Characterization of NUP98-Rearranged Pediatric Myeloid Neoplasms.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026
Same journal

Chromoanagenesis in Myelodysplastic Syndromes Is Associated With Highly Complex Karyotype, TP53 Disruption and Dismal Prognosis.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026
See all related articles

The Oncotype DX Recurrence Score (RS) shows promise for breast cancer prognosis. However, further validation is needed to confirm its independent value beyond traditional histopathology before clinical use.

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Biostatistics

Background:

  • The Oncotype DX assay provides a Recurrence Score (RS) for estrogen receptor-positive, lymph node-negative breast cancers.
  • Independent validation of its utility in routine clinical practice is limited.

Purpose of the Study:

  • To retrospectively evaluate the correlation between Oncotype DX Recurrence Score and standard histopathologic features.
  • To assess the predictive capability of histopathologic parameters for the Recurrence Score.

Main Methods:

  • Retrospective review of 42 breast carcinoma cases evaluated by Oncotype DX.
  • Analysis of tumor characteristics including size, histologic grade, ER, PR, and HER-2/neu status.
  • Correlation analysis between Recurrence Score and histopathologic data.

Related Experiment Videos

Main Results:

  • Recurrence Score significantly correlated with tubule formation, nuclear grade, mitotic count, ER, PR, and HER-2/neu status.
  • A predictive equation using these histopathologic features explained 66% of the Recurrence Score variability (R2=0.66).

Conclusions:

  • The Oncotype DX Recurrence Score is associated with key histopathologic features of breast cancer.
  • Further validation is required to establish its independent clinical utility beyond histopathology for decision-making.